Robert Sourk, MD
Pulmonary Disease · Hutchinson, KSNPI 1942272554
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,036 of the $32,749 with a category attached, or 64.2%. Mylan Specialty L.p. accounts for 95.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $18,225 and has fallen 97.5% since, to $464 in 2023. Among pulmonary disease clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 196 payments — averaging $167.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$31K
- Sunovion Pharmaceuticals Inc.$235
- Boehringer Ingelheim$223
- Harmony Biosciences LLC$162
- Jazz Pharmaceuticals Inc.$154
- AstraZeneca$147
- plus $676 from 12 others
What the payments were for
- Consulting fees$6,66420%
- Speaking & faculty fees$21,03664%
- Travel & lodging$2,5928%
- Food & beverage$2,3287%
- Education$1280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 90 | $31,153 |
| Sunovion Pharmaceuticals Inc. | 21 | $235 |
| Boehringer Ingelheim | 16 | $223 |
| Harmony Biosciences LLC | 8 | $162 |
| Jazz Pharmaceuticals Inc. | 9 | $154 |
| AstraZeneca | 11 | $147 |
| Genentech USA, Inc. | 8 | $125 |
| Grifols USA, LLC | 7 | $108 |
| Actelion Pharmaceuticals US, Inc. | 6 | $99 |
| GSK | 7 | $91 |
| Sanofi-aventis U.S. LLC | 1 | $58 |
| Merck | 4 | $56 |
| Regeneron Healthcare Solutions, Inc. | 2 | $43 |
| Gilead | 2 | $29 |
| Philips North America LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Novartis | 1 | $15 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$29,984
How this compares
$32,749 in reported general payments places this provider in the 90th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $14,405 |
| Budesonide | 16 | $4,939 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $3,163 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $649 |
| Lisinopril | 13 | $83 |
| Pioglitazone Hcl | 13 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $91 | $14,40521 claims |
| AstraZenecaSymbicort | $147 | $3,16318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 pulmonary disease providers in Kansas.
Other pulmonary disease in Hutchinson
- Moh'd Al-HalawaniHutchinson$15K
- Humayun AshrafHutchinson$14K
- Mario CastroKansas City$1.9M
- Matthew SharpeKansas City$602K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Abdel-Ghanie Abu-SamraWichita$60K
- Andreas SchmidKansas City$26K
- Harold BarkmanKansas City$24K
- Brandon BowersShawnee Mission$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.